X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

The New Head Office Tax System For The Cross-Border SMEs

Content Team by Content Team
14th September 2023
in News
The New Head Office Tax System For The Cross-Border SMEs

Small and medium-sized enterprises (SMEs) often encounter unfair competition while conducting business in Europe. To rectify this issue, the European Commission (EC) has introduced new measures through SME Relief Communication. These measures offer immediate relief, enhance long-term competitiveness, and promote equity within the European Single Market’s business landscape.

This initiative is designed to cater to the requirements of SMEs in the current economic climate.

The non-legislative proposals outlined in the SME Relief Communication include:

Enhancing the existing regulatory framework for SMEs by building on the successful application of the ‘one in one out principle,’ which resulted in €7.3 billion in net cost savings. Additionally, the Commission plans to improve the implementation of the SME Test and encourage the use of regulatory sandboxes to foster innovation and experimentation among SMEs.

Streamlining administrative procedures and reporting requirements for SMEs by introducing the Once-Only Technical System, set to launch by the end of 2023. This system will enable SMEs to complete administrative tasks across the Single Market without redundant document submissions. Furthermore, the Commission will continue its efforts to reduce reporting obligations by 25 percent, as announced in March 2023.

Increasing investment opportunities for SMEs, including ensuring that a portion of the proposed €7.5 billion EU guarantee within the new Strategic Technologies for Europe Platform (STEP) window of InvestEU is accessible to SMEs. A standardized methodology will assist SMEs in reporting sustainability data, simplifying access to sustainable financing.

Supporting employee training through initiatives like the Large Skills Partnerships under the European Pact for Skills to align workforce skills with the needs of European SMEs.

Promoting SME growth by reevaluating the current SME definition thresholds, developing a uniform definition, and potentially adjusting specific obligations for small mid-cap companies to unlock their full economic potential.

Introducing a Head Office Tax System directive for SMEs allows cross-border SMEs with permanent establishments to interact solely with the Head Office tax administration instead of dealing with multiple tax systems. This directive aims to enhance tax certainty, fairness, and cost-effectiveness while reducing the risk of double taxation and tax disputes. The anticipated reduction in compliance costs will facilitate investment and cross-border expansion within the EU, enabling these companies to fully leverage the freedom of establishment and the free movement of capital without undue tax-related hindrances.

Addressing late payments in commercial transactions by proposing new regulations to replace the 2011 Directive. The new rules include a stricter maximum payment limit of 30 days, eliminating ambiguities and addressing legal gaps in the existing directive.

In summary, these new measures will ensure timely payments to small businesses, simplify paperwork, and streamline taxation processes. Additionally, they will enhance SME access to talent and financing, facilitating their transition to digital and environmentally sustainable practices, as highlighted by Věra Jourová, European Commission Vice-President for Values.

Previous Post

Over 50% Of FDA-Approved Drugs To Incorporate AI By 2030

Next Post

Rentschler Biopharma UK Site Approved For AAV Production

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post

Rentschler Biopharma UK Site Approved For AAV Production

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In